FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308398371> ?p ?o ?g. }

• W4308398371 abstract "<h3>Background</h3> Adoptive and antibody-based immunotherapies are highly successful in the clinic for the treatment of certain malignancies. However, effective immunotherapy targets remain elusive for various cancers, in particular metastatic diseases. Certain existing targets often encounter antigen loss, leading to tumor relapse. Thus, it is crucial to discover novel cell surface targets that are essential for tumor sustenance and metastasis, and thus less prone to immunotherapeutic escape. <h3>Methods</h3> To uncover crucial cell surface proteins that drive anoikis-resistance and metastasis, we performed an integrated analysis of the global proteome and acute translatome in distinct oncogene-transformed and non-transformed cells in 3D cultures. Anoikis-resistance <i>in vitro</i> and metastasis <i>in vivo</i> were measured by 3D spheroid cultures and a murine renal subcapsular implantation metastasis model, respectively. Candidate surface targets from the screens were evaluated by immunohistochemistry using tissue microarrays (TMAs) of multiple human cancers, and TMAs consisting various adult and pediatric normal tissues. Phage-display biopanning was performed to identify single-domain VH binders, based on which CAR-T cells and a panel of humanized IgG1 antibody-drug conjugates (ADCs) were engineered. The CAR-T cells and ADCs were tested both <i>in vitro</i> and <i>in vivo</i> using murine tumor xenograft models. <h3>Results</h3> The screens identified that distinct oncoproteins such as mutant KRas^G12V, KRas^G13D, ETV6-NTRK3, and EWS-FLI1 each upregulate IL1RAP (IL-1 receptor accessory protein) to suppress tumor cell anoikis. IL1RAP is highly expressed on cell surface in multiple malignancies, including Ewing sarcoma (EwS), melanoma, pancreatic ductal adenocarcinoma, high-grade astrocytoma, glioblastoma, and ALK+ anaplastic large cell lymphoma. Genetic <i>IL1RAP</i> inactivation in EwS triggers anoikis and ferroptosis <i>in vitro</i> and impedes metastasis <i>in vivo</i>. Importantly, IL1RAP is minimally expressed in pediatric and adult normal tissues and blood cells, nominating IL1RAP as a promising surface target for immunotherapy. We identified a panel of novel and highly specific IL1RAP binders via phage-display biopanning, and engineered IL1RAP CAR-T cells and anti-IL1RAP ADCs conjugated to cytotoxic payloads such as pyrrolobenzodiazepine (PBD) dimer and Duocarmycin SA. IL1RAP CAR-T cells and anti-IL1RAP ADCs induced massive cell killing in a panel of EwS cells <i>in vitro</i>. Although the efficacy of IL1RAP CAR-T cells in murine EwS xenografts was limited by an immune suppressive tumor microenvironment, the anti-IL1RAP ADCs effectively limited EwS tumor progression at low doses such as 0.1mg/kg. <h3>Conclusions</h3> Therefore, we have defined surface IL1RAP as an immunotherapy target in EwS and potentially other human malignancies, and our pre-clinical studies suggest anti-IL1RAP ADCs as a highly promising immunotherapy strategy. <h3>Acknowledgements</h3> We thank the funding support from the NIH U54 Pediatric Immunotherapy Discovery and Development Network (1U54CA232568-01), a St. Baldrick’s Foundation/American Association for Cancer Research/Stand Up to Cancer Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT-27-17), and a St. Baldrick’s Foundation/Martha’s Better Ewing Sarcoma Treatment (BEST) Grant (#663113). H.-F. Zhang is funded by a fellowship from the Canadian Institutes of Health Research (#415377) and a trainee award from the Michael Smith Foundation for Health Research partnered with the Lotte and John Hecht Memorial Foundation (#18569)." @default.
• W4308398371 created "2022-11-11" @default.
• W4308398371 creator A5000432967 @default.
• W4308398371 creator A5005449207 @default.
• W4308398371 creator A5011919938 @default.
• W4308398371 creator A5017546318 @default.
• W4308398371 creator A5040570196 @default.
• W4308398371 creator A5046393134 @default.
• W4308398371 creator A5051219791 @default.
• W4308398371 creator A5052593466 @default.
• W4308398371 creator A5083608565 @default.
• W4308398371 creator A5089862290 @default.
• W4308398371 date "2022-11-01" @default.
• W4308398371 modified "2023-10-16" @default.
• W4308398371 title "1192 Identification of oncogene-induced surface protein IL1RAP as an immunotherapy target in multiple cancers" @default.
• W4308398371 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1192" @default.
• W4308398371 hasPublicationYear "2022" @default.
• W4308398371 type Work @default.
• W4308398371 citedByCount "0" @default.
• W4308398371 crossrefType "proceedings-article" @default.
• W4308398371 hasAuthorship W4308398371A5000432967 @default.
• W4308398371 hasAuthorship W4308398371A5005449207 @default.
• W4308398371 hasAuthorship W4308398371A5011919938 @default.
• W4308398371 hasAuthorship W4308398371A5017546318 @default.
• W4308398371 hasAuthorship W4308398371A5040570196 @default.
• W4308398371 hasAuthorship W4308398371A5046393134 @default.
• W4308398371 hasAuthorship W4308398371A5051219791 @default.
• W4308398371 hasAuthorship W4308398371A5052593466 @default.
• W4308398371 hasAuthorship W4308398371A5083608565 @default.
• W4308398371 hasAuthorship W4308398371A5089862290 @default.
• W4308398371 hasBestOaLocation W43083983711 @default.
• W4308398371 hasConcept C121608353 @default.
• W4308398371 hasConcept C126322002 @default.
• W4308398371 hasConcept C152000582 @default.
• W4308398371 hasConcept C203014093 @default.
• W4308398371 hasConcept C2777701055 @default.
• W4308398371 hasConcept C2779013556 @default.
• W4308398371 hasConcept C2781187634 @default.
• W4308398371 hasConcept C502942594 @default.
• W4308398371 hasConcept C526805850 @default.
• W4308398371 hasConcept C71924100 @default.
• W4308398371 hasConcept C86803240 @default.
• W4308398371 hasConcept C8891405 @default.
• W4308398371 hasConceptScore W4308398371C121608353 @default.
• W4308398371 hasConceptScore W4308398371C126322002 @default.
• W4308398371 hasConceptScore W4308398371C152000582 @default.
• W4308398371 hasConceptScore W4308398371C203014093 @default.
• W4308398371 hasConceptScore W4308398371C2777701055 @default.
• W4308398371 hasConceptScore W4308398371C2779013556 @default.
• W4308398371 hasConceptScore W4308398371C2781187634 @default.
• W4308398371 hasConceptScore W4308398371C502942594 @default.
• W4308398371 hasConceptScore W4308398371C526805850 @default.
• W4308398371 hasConceptScore W4308398371C71924100 @default.
• W4308398371 hasConceptScore W4308398371C86803240 @default.
• W4308398371 hasConceptScore W4308398371C8891405 @default.
• W4308398371 hasLocation W43083983711 @default.
• W4308398371 hasOpenAccess W4308398371 @default.
• W4308398371 hasPrimaryLocation W43083983711 @default.
• W4308398371 hasRelatedWork W2044046394 @default.
• W4308398371 hasRelatedWork W2095050670 @default.
• W4308398371 hasRelatedWork W2119783541 @default.
• W4308398371 hasRelatedWork W2602917813 @default.
• W4308398371 hasRelatedWork W2604422439 @default.
• W4308398371 hasRelatedWork W3000945797 @default.
• W4308398371 hasRelatedWork W3200489044 @default.
• W4308398371 hasRelatedWork W4224277295 @default.
• W4308398371 hasRelatedWork W4362542628 @default.
• W4308398371 hasRelatedWork W4362567977 @default.
• W4308398371 isParatext "false" @default.
• W4308398371 isRetracted "false" @default.
• W4308398371 workType "article" @default.